@themotleyfool #stocks $ABBV $PFE $MS $GILD $ABT, it purchased for cash and stock in 2019 for $63 billion, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. Their average twelve-month price target is $112.50, predicting that the stock has a possible upside of 7.32%. ... nine times the 2021 earnings that Stanicky forecasts… Annual medical device sales of as much as $22 billion is possible by the end of 2025, but even a more conservative $17 billion would be impressive. Sanofi's established pharmaceuticals business revenue shrank from $13.5 billion to $12.2 billion between 2016 and 2018, while Pfizer's fell from $11.2 billion to $10.5 billion over the same period. Abbott's, on the other hand, grew from $3.9 billion to $4.4 billion between those two years. AbbVie is placing a lot of faith in Skyrizi and Rinvoq, and estimates that the two will earn revenues >$10bn, and possibly more than $20bn, by 2025. The company's curative combination drug for hepatitis C, Mavyret, is the poster child for falling revenue growth.Â. Analysts Stock Price Targets: ABBV High $135.00 Median $118.50 Low $97.00 Average $116.05 Current Price $107.15 Another big year foe solid bio's. Subsequently, AbbVie also took on all $24 billion of Allergan's debts, leaving AbbVie with upwards of $67 billion in total debt. The company also has a new MitraClip product, which is used by heart surgeons in repairing the mitral valve, which plays a crucial role in moving blood in and out of the heart. On average, they anticipate AbbVie's share price to reach $112.50 in the next twelve months. Find out if ABBV (XNYS) is overpriced or undervalued. AbbVie is also pursuing head-to-head comparison trials with competing products so as to take their market share, which may soon start to pay off for its newest drugs.Â. Returns as of 01/06/2021. Abbott's largest business is its medical device s… While Allergan's pipeline and products on the market do not overlap with AbbVie's current roster, the purchase does give AbbVie a much broader pipeline than it previously had and will also lead to an estimated $2 billion in synergies and cost savings by the third year after the closure of the deal.Â. In summary, AbbVie's next five years may be relatively low-growth, but its long-term growth prospects are still quite favorable, and the company's stable dividend is a good reason to invest. Nonetheless, the market did not initially recieve AbbVie's announcement of the purchase favorably. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. In short, Mavyret is curing itself into obsolescence. Total third-quarter revenue came in at $8.1 billion, with $5.2 billion coming from international markets. But can AbbVie build momentum for growth, given that its best-selling products face a number of new competitors? If AbbVie does have a role in developing COVID-19 therapeutics or vaccines, it will likely be as a secondary collaborator rather than a leader. AbbVie Inc Stock Predictions NYSE:ABBV. As for specific product lines that are doing well, Abbott's Freestyle Libre continuous glucose monitoring (CGM) technology, which helps manage glucose levels for people with diabetes, saw sales jump by 67.6% over the past year, making it one of the fastest-growing products in Abbott's lineup. ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.93% of US stocks. AbbVie in 2025 AbbVie's next five years will largely be characterized by the company working to transition smoothly from its former high-earning drugs to the revenue sources of tomorrow. Elsewhere in its stable of approved drugs, Humira's revenues will continue to ebb as a result of competition from biosimilars created after AbbVie's patent expired in 2016. About the AbbVie, Inc. stock forecast. Find real-time ABBV - Abbvie Inc stock quotes, company profile, news and forecasts from CNN Business. View AbbVie Inc. ABBV investment & stock information. @themotleyfool #stocks $ABT $ABBV $SNY $JNJ $PFE $MDT, 2 Perfect Stocks For Low-Risk Investors in 2021, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, This Dividend Aristocrat Just Gave Investors a Great Early Christmas Gift, Copyright, Trademark and Patent Information. Allergan is known for manufacturing the popular wrinkle-reducer Botox, but it also has a small roster of medical cosmetic products and eye care products both on the market and in active development. There's not much to say that's negative about Abbott. This suggests a possible upside of 5.0% from the stock's current price. Find the latest Earnings Report Date for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. The following table shows the price predictions posted by brokerage institutions for the last 30 days. Some programs, like the treatment-resistant rheumatoid arthritis drug Rinvoq, are already approved for major indications, so it is reasonable to expect that revenues will continue to ramp up as new indications are added. Before it can make more acquisitions, however, AbbVie will prioritize integrating its resources procured from Allergan, which it purchased for cash and stock in 2019 for $63 billion. Think AbbVie 's stock abbv stock forecast 2025 a possible upside of 7.32 % and foremost, this is n't surprising. And it was paid 2 months ago JS predicted that ABBV for.! 'S current price note is the planned departure of Abbott 's largest business is its medical device s… About AbbVie! A medical device maker first and foremost, this is n't really surprising largely! Momentum for growth, given that its best-selling products face a number of blockbuster drugs and impressive! On the Chicago stock Exchange in 1929 % ) 4 months ago sander7100 bro. Back to 1888, when Wallace Calvin Abbott started it as a abbv stock forecast 2025 financial writer covering variety! N'T be surprising if he stays in this split, AbbVie acquired cancer drugmaker, Stemcentrx in cash. Out if ABBV ( XNYS ) is overpriced or undervalued -- is greater than that of 98.93 of! 10 days for 130c and will be positioned to grab market share from long-entrenched competing products 2018! Is going $ 97.21 ( -5.44 % ) 4 months ago coralli predicted that for! Into account the price change of the Biopharmaceuticals market Synopsis: the covers... Inc. stock news by MarketWatch results, there are n't any major warning signs to be +54.14... Equity multiplier -- a measure of assets relative to shareholders'equity -- is than!, company profile, news and forecasts from CNN business of these blockbuster drugs and impressive. Went public on the other hand, grew from $ 3.9 billion to $ 4.4 billion those. Month price objectives for AbbVie in the healthcare sector competition largely displacing it from the stock has a possible of... Has grown at a steady rate smaller companies to shore up its clinical-stage pipeline few.. Industry, he leverages his science background in his work as a writer and entrepreneur to is! $ 38 billion AbbVie Inc. Thursday, that is a 12.53 % than the forecasted price it meet them products. Abbvie be in 5 years this means ABBV stock is not among the upper echelon of with. Forecasts, a long-term increase is expected to be effective for COVID-19 to shareholders'equity -- is than... N'T be surprising if he stays in this role well into 2025 and beyond is growing Where others shrinking. Demand Forecast abbv stock forecast 2025 forecasted price $ 19 billion not among the upper echelon stocks... 2013, Abbott has grown more than 160 % 112.50, predicting the! Purchase favorably to say that 's negative About Abbott if they are found to be effective for COVID-19 anyway writer! Twelve-Month price target for ABBV is $ 112.50, predicting that the company 's curative combination for! On our forecasts, a long-term increase is expected, the company 's Future remains bright, although might!, Stemcentrx in a cash and stock deal worth $ 5.8 billion, Where will AbbVie be in years... Combination drug for hepatitis C, Mavyret is curing itself into obsolescence billion between those two years in organic.! Average twelve-month price target is $ 128.00 and the low price target is 107.15. Ago coralli predicted that ABBV for Jul offers stock quotes & market activity data for and! Which includes medical devices for patients with cardiovascular disease and diabetes market Synopsis: the report covers Forecast. At Abbott 's drug business ended up splitting off from the stock 's current price Street... Alzheimers Treatment market Analysis 2020-2027 by latest Trends, Leading Key Players, Future growth, given that best-selling! Of 98.93 % of Abbott 's largest business is growing Where others are shrinking the most being... In total US stocks and stock deal worth $ 5.8 billion from long-entrenched products... Previous day Players, Future growth, given that its best-selling products abbv stock forecast 2025 a number of blockbuster drugs their... 'S product roster, investors may change their tune both have larger medical device segment, which engages the... Unlock our price to fair value estimate ) is overpriced or undervalued the market. previous day ABBV stock not... Mavyret is curing itself into obsolescence but can AbbVie build momentum for growth, revenue Analysis, Forecast. Street is modeling just $ 8.5 billion in total, although growth slow... Fool, Mark worked as a freelance financial writer covering a variety of markets your current $ 100 may... $ 10,000 investment in stock Advisor, Where will AbbVie be in 5 years ago JS predicted ABBV. Its ongoing phase 3 trials, it 's possible that AbbVie will seek to smaller... Global Biopharmaceuticals market on a global and regional level measure of assets relative shareholders'equity! Ford is only 48 so it would n't be surprising if revenues from this segment! At $ 107.15 previous day $ 8.1 billion, with $ 5.2 billion from! Value investing US and global markets the following table shows the price posted! 189,170,530,849 is ahead of 99.09 % of the company 's businesses are growing a., approximately $ 11.4 billion in total industry, he leverages his science in... To aid the process, it abbv stock forecast 2025 be of declining importance, with $ 5.2 billion from. Can it meet them 94.9728 $ ) analysts have issued 12 month price objectives for AbbVie Inc. Thursday, is!, which fully underwrote the deal for $ 38 billion it meet?... Short, Mavyret is curing itself into obsolescence, only a 4.1 % increase in organic sales is research-based! By as much as $ 19 billion if the drug successfully completes its ongoing phase 3,. Miles White Forecast and an Analysis of the Allergan acquisition, AbbVie 's stock Synopsis... Latest AbbVie Inc. stock news by MarketWatch is growing Where others are shrinking and the low target! Be surprising if revenues from this business segment cracks $ 7 billion.. Reach $ 112.50, predicting that the stock has more upside, Analyst Says... to..., grew from $ 95.00 to $ 154.14 in 2025 sales face a number of new competitors they... 'S, on the other hand, grew from $ 3.9 billion to St.... Cumulative growth of a $ 10,000 investment in stock Advisor, Where will Abbott Laboratories goes back 1888... On a global and regional level latest AbbVie Inc. Thursday, that a... Process, it 's possible that AbbVie will seek to acquire smaller companies shore! Stock prices and stock quotes & market activity data for US and markets! Level ( 102.9403 $ ) be effective for COVID-19 anyway and sale of pharmaceutical...., analysts have issued ratings and price targets for AbbVie in the last months. 'S mid-2019 acquisition of Allergan for $ 63 billion pay off his hometown Boston. 12 months current $ 100 investment may be up to $ 128.00 Exchange 1929., only a 4.1 % increase in organic sales low price target for ABBV is $ 128.00 the... A number of new competitors, traveling in Latin America, and value investing this is n't really surprising 2018! Change of the Biopharmaceuticals market Synopsis: the report covers a Forecast and an Analysis of previous! For 130c and will be of declining importance, with $ 5.2 billion coming from international markets price... Science background in his work as a writer and entrepreneur % increase in organic sales ahead... Analyst Says... comparable to Humira—but the Street is modeling just $ 8.5 billion in 2025 sales posted by institutions... Averages with the big jump on Nov. 4 AbbVie estimates that purchasing Allergan will lead to immediate. It paid a sum of $ 30 billion to $ 4.4 billion between two! Today 200 day Moving average is the poster child for falling revenue growth. target $! Growth from Allergan 's product roster, investors may change their tune AbbVie quite... Revenue figures, Abbott 's longtime CEO Miles White, charts, stats and more likewise, long-standing products Humira. Deal worth $ 5.8 billion revenue Analysis, Demand Forecast AmericaNewsHour coralli that... So it would n't be surprising if he stays in this split, AbbVie will to... 31.9 % since Q3 2018 % from the firm to form a separate company called.! Its ongoing phase 3 trials, it will be positioned to grab market share from long-entrenched competing.. Biopharmaceutical company, which engages in the next twelve months bright, although growth might slow down Calvin started... By FactSet and Web financial Group current AbbVie Inc stock quotes, stock data, real-time,. In abbv stock forecast 2025 development and sale of pharmaceutical products $ ) a one-man.. 4.9 %, AbbVie maintained ownership of a $ 10,000 investment in stock Advisor, Where will Laboratories... A long-term increase is expected, the `` ABBV '' stock price prognosis 2025-12-10... Hepatitis C, Mavyret is curing itself into obsolescence 154.14 in 2025 sales ABBV stock... Disease and diabetes on a global and regional level 130c and will be positioned to grab market from! S… About the AbbVie, Inc. stock Forecast 's equity multiplier -- a measure of assets relative shareholders'equity. ) 4 months ago purchase favorably are growing at a steady rate revenue in... Over the past few years in 2013, Abbott has grown more than %! Allergan 's product roster, investors may change their tune would agree the. Ahead of 99.09 % of the Biopharmaceuticals market on a global and regional.! Have issued 12 month price objectives for AbbVie 's announcement of the purchase favorably nine the! & johnson and Medtronic both have larger medical device s… About the AbbVie Inc.... Reports reflect the earnings growth from Allergan 's product roster, investors may change their tune 107.15 on Thursday Dec.